This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Newman, C. B Articles by Fuller, J. H Search for Related Content PubMed PubMed Citation Articles by Newman, C. B Articles by Fuller, J. H Social Bookmarking                         What's this?

The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS)

Department of Medicine, New York University School of Medicine, VA Hospital, 423 East 23rd Street, Dept of Medicine –11093 South, New York, NY 10010, US.

Michael Szarek

Pfizer Inc, 235 East 42nd Street, New York, NY 10017, US.

Helen M Colhoun

Division of Medicine & Therapeutics, Level 7, Ninewells Hospital & Medical School, Dundee, DD1 9SY, UK.

D John Betteridge

Department of Medicine, Royal Free and University College Medical School, Jules Thorn Institute, Middlesex Hospital, Mortimer St, London, W1N 8AA, UK.

Paul N Durrington

Cardiovascular Research Group, University of Manchester, 46 Grafton Street, Manchester, M13 9NT, UK.

Graham A Hitman

Centre for Diabetes and Metabolic Medicine, Queen Mary's School of Medicine, University of London, London, E1 1BB, UK.

H Andrew W Neil

Division of Public Health and Primary Health Care, University of Oxford, Old Road Campus, Headington, Oxford, OX3 7LF, UK.

David A Demicco

Pfizer Inc, 235 East 42nd Street, New York, NY 10017, US.

Sheila Auster

Pfizer Inc, 235 East 42nd Street, New York, NY 10017, US.

John H Fuller

Department of Epidemiology & Public Health, University College, 1–19 Torrington Place, London, WC1E 6BT, UK.

The objective of this study was to evaluate the safety and tolerability of atorvastatin 10 mg compared with placebo in 2,838 patients with type 2 diabetes and no history of coronary heart disease who were enrolled in the Collaborative Atorvastatin Diabetes Study (CARDS) and followed for 3.9 years.

The percentages of patients experiencing treatment-associated adverse events (AEs), serious AEs and discontinuations due to AEs in the atorvastatin (n=1,428) and placebo (n=1,410) groups were 23.0% vs. 25.4%, 1.1% vs. 1.1% and 2.9% vs. 3.4%, respectively. The most common treatment-associated AEs in the atorvastatin and placebo groups were digestive system-related (8.9% vs. 10.0%). All-cause and treatment-associated myalgia were reported in 4.0% and 1.0% of atorvastatin-treated patients, and 4.8% and 1.2% of placebo-treated patients. An analysis of selected AEs by tertiles of baseline low-density lipoprotein (LDL) cholesterol showed no relationship between LDL cholesterol levels and the incidence of myalgia, cancer or nervous system AEs in either treatment group.

Overall, these data demonstrate that atorvastatin 10 mg was well tolerated in patients with type 2 diabetes during long-term treatment.

Key Words: adverse effects of treatment • CARDS • lipids • statin • trials • type 2 diabetes

References

• 1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• 2. Cannon CP Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–504.[Abstract/Free Full Text]
• 3. Sever PS Dahlöf B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–58.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• 4. Baigent C Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• 5. LaRosa JC Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425–35.[Abstract/Free Full Text]
• 6. Pedersen TR Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437–45.[Abstract/Free Full Text]
• 7. Amarenco P Bogousslavsky J, Callahan A, 3rd et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549–59.[Abstract/Free Full Text]
• 8. American Diabetes Association. Standards of medical care in diabetes–2007. Diabetes Care 2007;30(suppl 1):S4–S41.[Free Full Text]
• 9. Wood D Wray R, Poulter N et al. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(suppl 5):v1–v52.[Free Full Text]
• 10. Newman CB Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 2003;92:670–6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• 11. Newman C Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006;97:61–7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• 12. Nissen SE Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071–80.[Abstract/Free Full Text]
• 13. Colhoun HM Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–96.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• 14. Collins R Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005–16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• 15. Sever PS Poulter NR, Dahlöf B et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005;28:1151–7.[Abstract/Free Full Text]
• 16. Colhoun HM Thomason MJ, Mackness MI et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med 2002;19:201–11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• 17. Thomason MJ Colhoun HM, Livingstone SJ et al. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabet Med 2004;21:901–05.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• 18. Pasternak RC Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical Advisory on the use and safety of statins. Circulation 2002;106:1024–8.[Free Full Text]
• 19. Shepherd J Barter P, Carmena R et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006;29:1220–6.[Abstract/Free Full Text]
• 20. Parris ES Lawrence DB, Mohn LA, Long BL. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005;28:595–9.[Abstract/Free Full Text]
• 21. LaRosa JH LaRosa CJ. Enhancing drug compliance in lipid-lowering treatment. Arch Fam Med 2000;9:1169–75.[Abstract/Free Full Text]
• 22. Zocor [package insert]. Whitehouse Station, NJ: Merck & Co. Inc; 2005.
• 23. Crestor [package insert]. Wilmington, DE: AstraZeneca; 2005.
• 24. Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781–90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• 25. de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004;24:584–91.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• 26. Sabatine MS Wiviott SD, Morrow DA, McCabe CH, Cannon PC. Highdose atorvastatin associated with worse glycemic control: A PROVE IT–TIMI 22 substudy. Circulation 2004;110(suppl):III–834.
• 27. Holman RR Neil A Results of AFORRD trial. Diabet Med 2006;23(suppl 4):635.[Web of Science][Medline] [Order article via Infotrieve]
• 28. Holman RR, Neil HAW, for the AFORRD Study Group Atorvastatin in factorial with omega-3 fatty acids risk reduction in diabetes. Late-breaking presentation at the International Diabetes Federation 19th World Diabetes Congress, December 3–7, 2006, Cape Town, South Africa.
• 29. Knopp RH d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006;29:1478–85.[Abstract/Free Full Text]
• 30. Grundy SM Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39.[Abstract/Free Full Text]
• 31. Wiviott SD Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005;46:1411–16.[Abstract/Free Full Text]
• 32. Heart Protection Study Collaborative Group. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Med 2005;3:6.[CrossRef][Medline] [Order article via Infotrieve]

Diabetes and Vascular Disease Research, Vol. 5, No. 3, 177-183 (2008)
DOI: 10.3132/dvdr.2008.029


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Newman, C. B Articles by Fuller, J. H Search for Related Content PubMed PubMed Citation Articles by Newman, C. B Articles by Fuller, J. H Social Bookmarking                         What's this?